PARIS, May 11, 2012 /PRNewswire/ --
Boston Scientific Corporation (NYSE: BSX) announces extended warranties of up to 10 years, depending on the model, for its ENERGEN(TM) and INCEPTA(TM) implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The new warranty program is the longest available in the industry and provides physicians, patients and payers across Europe warranties up to five years longer than other currently-marketed cardiac devices. Following are the devices and their warranties.
- ENERGEN and INCEPTA VR ICD, 10-year device warranty - ENERGEN and INCEPTA DR ICD, 8-year device warranty - ENERGEN and INCEPTA CRT-D, 6-year device warranty
"Having such a warranty for devices gives physicians assurance about longer battery life and can provide patients with greater peace of mind. This is a major factor to consider when selecting a specific device to implant," said Dr. Oliver Przibille, FESC, CCB, Herzschrittmacher-Centrum, Frankfurt, Germany.
"We believe the extended warranty program provides a strong foundation for Boston Scientific's latest generation of ICDs and CRT-Ds as well as our development plan for future devices. It also confirms our continuous engagement efforts with physicians and patients and our role as an innovator in the cardiac rhythm management field," said Michael Onuscheck, senior vice president and president of Europe, Middle East and Africa at Boston Scientific.
Together with medications, lifestyle changes and other surgical options, ICDs and CRT-Ds are used to improve heart function and rhythm. These devices offer life-saving benefits by preventing sudden cardiac death, and they play an important role in treating heart failure, a progressive condition in which a damaged heart cannot pump blood effectively. Boston Scientific's ICDs and CRT-Ds benefit from the company's longer-lasting batteries, which could lead to fewer implants over a patient's life, potentially resulting in reduced patient health complications and reduced healthcare system costs.
"From a psychological point of view, an extended warranty has an extremely positive effect on a patient's perception and acceptance of this therapy, because a long warranty means the manufacturer is confident about the longevity of its devices," said Dr. Roberto Verlato, head of cardiology department, Camposampiero Hospital, Italy.
Boston Scientific's warranty program is based on real-world data from more than 67,000 devices, which include the company's advanced battery technology that offers greater capacity compared to other ICD and CRT-D batteries and includes numerous energy-saving features.
Currently, 14 million Europeans have heart failure, and this number may rise to 30 million by 2020 as a result of the aging population and the effectiveness of recent treatments to lengthen patients' survival. Heart failure is associated with frequent hospital admissions, which represent the main driver of treatment costs (67-75 percent). On average, heart failure treatment costs amount to 1-2 percent of each country's total healthcare budget in Europe.
To view more information on the Boston Scientific warranty program, visit http://www.epresspack.net/bsci.
1) Data as of August 2011 from LATITUDE(TM)-monitored patients with Boston Scientific devices.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our warranty programs, technology, product performance, clinical outcomes, the market for heart failure devices in Europe, competitive offerings and our business plans. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Clients in focus...